Replies to post #1039 on Revive Therapeutics Ltd (RVVTF)

[powerbattles]

Revive Therapeutics: Analyst sees 'substantial upside potential' as key assets move towards clinic


Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a well-established safety profile having been prescribed for arthritis for more than 30 years. Revive Therapeutics has made an IND filing concerning the use of BUC to treat COVID-19 with intellectual property around infectious diseases.

https://www.proactiveinvestors.co.uk/companies/news/923070/revive-therapeutics-analyst-sees--substantial-upside-potential--as-key-assets-move-towards-clinic-923070.html